In silico oncology: Part ii—clinical requirements regarding in silico oncology

Multiscale Cancer Modeling

Volumn , Issue , 2010, Pages 437-445

  Graf, Norbert ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84874576971     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/b10407     Document Type: Chapter

References (18)

1. WHO: http://www.who.int/mediacentre/factsheets/fs297/en/index.html (last accessed 07/19/2009).
2. Couzin, J. 2007. Survival in young adults with Cancer. Science 317:1160-1162.
3. Pritchard-Jones, K. et al. 2008. Improving recruitment to clinical trials for cancer in childhood. The Lancet Oncol 9:392-399.
4. Graf, N. and Göbel, U. 2004. Therapieoptimierungsstudien der Gesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH) und 12. Novelle des Arzneimittelgesetzes zur Umsetzung der EU-Richtlinie. Klin Pädiatr 216:129-131.
5. Göbel, U. and Jürgens, H. 2003. Translation der kliniknahen Grundlagen-forschung in der pädiatrischen Onkologie. Klin Pädiatr 215:289-290.
6. Graf, N. et al. 2008. Post-genomic clinical trials: The perspective of ACGT. eCancerMedicalScience J, (online journal) 1, Article Num. 66, DOI:10.3332/eCMS.2007.66.
7. Bogaerts, J. et al. 2009. Individual patient data analysis to assess modifications to the RECIST criteria. EJC 45:248-260.
8. Therasse, P. et al. 2000. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216.
9. Huff, C.A. et al. 2006. The paradox of response and survival in cancer therapeutics. Blood 107:431-434.
10. Tsiknakis, M. et al. 2008. A semantic grid infrastructure enabling integrated access and analysis of multilevel biomedical data in support of post-genomic clinical trials on Cancer. IEEE Trans Information Technology in Biomedicine, Special issue on Bio-Grids 12:191-204.
11. Stamatakos, G. et al. 2002. In silico radiation oncology: combining novel simulation algorithms with current visualization techniques, Proc. IEEE, Special Issue on Bioinformatics: Advances and Challenges 90:1764-1777.
12. Friedrich, C.M. and Paterson, T.S. 2004. In silico predictions of target clinical efficacy. Drug Disc Today 3:216-222.
13. Michelson, S. 2006. In silico prediction of clinical efficacy. Curr Opin Biotechnol 17:666-670.
14. Noble, D. 2002. Modeling the heart—from genes to cells to the whole organ. Science 295:1678-1682.
15. Ho, R.L. and Bartsell, L.T. 2004. Biosimulation software is changing research. Biotechnol Annu Rev 10:297-302.
16. Deisboeck, T.S. et al. 2009. In silico cancer modeling: is it ready for prime time? Nat Clin Pract Oncol 6:34-42.
17. Graf, N. and Hoppe, A. 2006. What are the expectations of a clinician from in silico oncology? In Marias K, Stamatakos G (Hrsg). Proc. 2nd Int Adv Res Workshop on In Silico Oncology, Kolympari, Chania, Greece, September 25-26, 2006, pp. 36-38 (http://www.ics.forth.gr/bmi/2nd-iarwiso/; last accessed 07/19/2009).
18. Graf, N. et al. 2009. “In Silico” oncology for clinical decision-making in the context of nephroblastoma. Klin Pädiatr 221:141-149.